Neuroendocrine Tumor Treatment Market Size, Share & Trends Report

Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Site (Small Intestine, Pancreas), By End Use (Hospitals, Clinics), By Product (SSA, Targeted Therapy), And Segment Forecasts, 2018 - 2025

  • Published Date: Nov, 2018
  • Base Year for Estimate: 2017
  • Report ID: GVR-2-68038-624-0
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 100

Industry Insights

The global neuroendocrine tumor treatment market size was estimated at USD 1.51 billion in 2017 and is expected to register a CAGR of 10.4% during the forecast period. Increasing cases of neuroendocrine tumors (NETs) are expected to accelerate the demand for treatment options, thereby augmenting the market growth over the forecast period. This is a rapidly advancing field as the novel therapies and diagnostic products are being developed.

U.S. neuroendocrine tumor treatment market

Some of the ongoing clinical trials include RAD 001 to treat advanced midgut NETs, Lanreotide Autogel for non-functional tumors, and NET-01 chemotherapy for pancreatic tumors.

Ongoing R&D activities in detection techniques, such as Ga labeled radionucleotide therapies and radiofrequency ablation technique, are the major factors driving the demand NET treatment market.

For instance, PSMA Targeted PET Imaging Agent by Progenics Pharmaceuticals, Inc. is under clinical trial phase and is expected to help treat prostate cancer. Heavy investments in the field by cancer research organizations and governments across the globe is another key factor propelling the NET market growth.

For instance, organization, such as The Neuroendocrine Tumor Research Foundation (NETRF), invested more than USD 1.5 million in the development of advanced radiation therapy named Peptide Receptor Radionuclide Therapy (PRRT). In addition, growing Patient Assistance Programs (PAPs), government initiatives for cancer awareness, and extensive R&D by pharmaceutical companies are expected to propel the market growth in the next few years.

Product Insights

The Somatostatin Analogs (SSAs) and targeted therapy are widely used for the treatment of neuroendocrine carcinoma as they control cancer growth, symptoms, and target biomarkers. SSAs product segment accounted for the largest revenue share as of 2017 owing to safe treatment procedure offered by SSAs.

SSAs are generally used to treat patients who are resistant to radiation therapy and surgery. Many SSAs are currently under clinical trial phase and waiting for approval. Some of these are PEN-221 by Tarveda Therapeutics and DP1038 by Dauntless Pharmaceuticals.

Targeted therapy consists of drugs, such as Sunitinib and Everolimus. Due to fewer side effects associated with these drugs they are used as the first line of therapy for neuroendocrine carcinoma. The other products include chemotherapy, radiation therapy, surgery, andtyrosine kinase inhibitors.

Site Insights

Thesmall intestine segment accounted for the largest revenue share of the global neuroendocrine tumor treatment market in 2017 as GI tract is more prone to developing NETs. According to the statistics published in the investor presentation of Novartis in 2015, GI comprises 61% of the total NETs and among them, tumor in the small intestine was the most common one.

Moreover, statistics published by the American Society of Clinical Oncology (ASCO), in 2016, around 8,000 adults in U.S. were diagnosed with GI tract-carcinid tumor. This increasing prevalence of carcinoid tumor in GI tract is expected to drive the segment growth over the forecast period.

The pancreas segment is expected to have a steady growth during the next few years.Increasing R&D investments for the development of novel therapies for pancreatic NETs are expected to boost the segment expansion. For example, SUNITINIB by Pfizer Inc. is currently under phase III clinical trial and indicated to be used for pancreatic NETs.

End-use Insights

Hospital was the dominant end-use segment, in terms of revenue share, in 2017as a large number of procedures for diagnosis are performed in these facilities. The presence of developed technologies and availability of multiple options for NET diagnosis are expected to further augment the segment growth.

Global neuroendocrine tumor treatment market

Clinics segment is expected to witness lucrative growth in the coming years due to availability of skilled surgeons and patient-centric treatment options. The others segment includes cancer research organizations and government institutes and is likely to offer high growth potential for NET market in the years to come. .

Regional Insights

North America accounted for the highest market share in 2017 owing to supportive insurance policies in this region facilitating NET treatment, such as Medicare, Medicaid, and Tricare. Moreover, sophisticated healthcare facilities and high R&D expenditure by pharmaceutical companies and regional government for cancer research are other factors driving the North America market.

Asia Pacific market is anticipated to witness significant growth in the coming years due to rising incidence of NETs in the region. Increasing investments by the regional governments to tackle the high unmet clinical needs are also likely to help boost the market development.

Neuroendocrine Tumor Treatment Market Share Insights

The global market is highly competitive and is led by companies, such as Novartis AG; Boehringer Ingelheim International GmbH; Pfizer, Inc.; and Ipsen Pharma. Several other companies in the market include AVEO Oncology,Hutchison MediPharma Limited, and Progenics Pharmaceuticals.

Most of these companies have undertaken strategies, such as product launch, regional expansion, partnership and distribution agreements, to strengthen their makret position. For instance, in January 2018, Novartis AG announced to purchase all the ordinary shares from its subsidiary group Novartis Groupe France S.A., which includes Advanced Accelerator Applications S.A. (AAA).

In June 2018, Boehringer Ingelheim announced to invest USD 270 million to build new Biologicals Development Center (BDC) specialized for immunology and immune-oncology. The initiatives like these are expected to propel the market growth over the forecast period.

Report Scope

Attribute

Details

Base year for estimation

2017

Actual estimates/Historical data

2014 - 2016

Forecast period

2018 - 2025

Market representation

Revenue in USD Million & CAGR from 2018 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and MEA

Report coverage      

Revenue forecast, company share, competitive landscape, growth factors and trends

Country Scope

U.S., Canada, Germany, U.K., China, India, Mexico, Brazil, and South Africa

15% free customization scope (equivalent to 5 analysts working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of the customization


Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global neuroendocrine tumor treatment market report on the basis of product, site, end use, and region:

  • Product Outlook (Revenue, USD Million, 2014 - 2025)

    • Somatostatin Analogs (SSAs)

    • Targeted Therapy

    • Others

  • Site Outlook (Revenue, USD Million, 2014 - 2025)

    • Lungs

    • Pancreas

    • Colon

    • Small Intestine

    • Others

  • End-use Outlook (Revenue, USD Million, 2014 - 2025)

    • Hospitals

    • Clinics

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • India

    • Latin America

      • Mexico

      • Brazil

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified